Guardant Health Inc. stocks have been trading up by 7.81 percent after bullish coverage highlighted promising oncology diagnostics growth.
Click Here for a Millionaire's POV on Trading GH
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- FDA cleared Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim’s new HER2‑mutant lung cancer drug, adding a 27th indication to the Guardant Health platform.
- RBC Capital started coverage on GH with an Outperform rating and a Street‑high $185 price target, citing powerful structural growth drivers and pricing upside.
- Evercore ISI and Mizuho both boosted targets on GH, highlighting Guardant360 volume inflection, Shield catalysts, and a path to better profitability over time.
- Goldman Sachs and Wolfe Research launched bullish coverage on Guardant Health, calling GH a market leader in therapy selection and a top specialty diagnostics idea.
- June Form 4 filings show GH insiders selling shares but retaining sizable holdings, a data point traders track alongside the stronger fundamental and Street backdrop.
Live Update At 10:02:41 EDT: On Wednesday, July 01, 2026 Guardant Health Inc. stock [NASDAQ: GH] is trending up by 7.81%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
Guardant Health, ticker GH, has been trading like a momentum name rather than a sleepy diagnostics stock. Over the last few weeks, GH has run from a closing low near $124.89 on 2026/06/08 to about $161.59 on 2026/07/01. That’s a strong trend, with a stair‑step pattern of higher lows from the mid‑$120s to the mid‑$150s, capped by a recent breakout above $160.
Intraday, GH shows active trading and strong dip buying. On the latest session, the stock flushed quickly from the $160.75 open down toward $156.16, then snapped back and held near session highs around $161–$162 into 10:00. That’s classic accumulation behavior in a name traders are crowding into.
Fundamentally, Guardant Health is still a high‑growth, loss‑making story. GH booked roughly $982.0M in revenue over the trailing period, with revenue growing above 30% annually over three and five years. Gross margin is a hefty 64.9%, but operating margins are deeply negative, with EBIT margin around ‑39.8% and profit margin near ‑40.1%. Return on assets is also sharply negative.
More Breaking News
- SVRE Stock Slides As SaverOne Pushes Deeper Into Defense Deals
- KUST Stock Draws Traders As Volatility And Losses Mount
- Abivax ABVX Jumps As Obefazimod Data Redraws Street Targets
- MSTR Stock Pops As New Capital Framework Targets Buybacks And BTC Liquidity
The balance sheet, however, gives GH time. Guardant Health holds about $1.1B in cash and short‑term investments, a current ratio near 4.7, and working capital above $1.0B. Free cash flow in the latest quarter was roughly ‑$71.2M, so GH is still burning cash, but with substantial liquidity and no near‑term dividend commitments. For traders, this is a classic “grow first, profit later” setup being repriced as new catalysts hit.
Why Traders Are Watching Guardant Health Now
Guardant Health is in the middle of a powerful narrative shift, and traders are treating GH like a leader in precision oncology rather than a speculative lab story.
The big spark is the FDA. Guardant Health locked down approval for its Guardant360 CDx liquid biopsy as a companion diagnostic for Boehringer Ingelheim’s HER2‑mutant advanced non‑small cell lung cancer drug, Hernexeos. That single event matters for three reasons: it’s the 27th CDx indication on the Guardant360 platform, it plugs GH deeper into real‑world oncology workflows, and it opens more reimbursable test volume in a high‑value cancer segment. The market reaction was immediate, with GH trading more than 1% higher premarket after the approval hit.
Wall Street piled on. RBC Capital Markets initiated Guardant Health with an Outperform rating and a Street‑high $185 target, framing GH as a structural growth story in an underpenetrated metastatic cancer testing market. Mizuho lifted its GH target from $135 to $175, leaning on that same Guardant360 approval plus Shield‑related catalysts it expects to drive the next phase of revenue growth and better margins.
Goldman Sachs started GH at Buy with a $165 target, highlighting FDA clearance of a 740‑gene G360 CDx panel, a ramp in tissue‑based therapy selection tests, and an upcoming tumor‑informed MRD product. Wolfe Research named Guardant Health its top idea in specialty diagnostics with a $150 target, while Evercore ISI and Bernstein both upgraded or re‑initiated GH at Outperform with targets of $160 and $175.
Put together, traders see Guardant Health as a multi‑product, multi‑catalyst platform: Guardant360 for therapy selection, Reveal and MRD for recurrence monitoring, and Shield for screening. The Street’s targets now cluster well above recent prices, giving momentum traders a clear reference for potential upside while they watch volume and news flow.
Conclusion
For active traders, GH is the kind of story that shows up again and again on the biggest‑gainers list: strong chart, big news, and a crowd of analysts racing to raise targets. Guardant Health has real growth, with nearly $1.0B in revenue, high gross margins, and a technology platform that keeps securing new FDA companion diagnostic wins like the latest Hernexeos indication. That validation helps explain why Guardant Health has been grinding higher from the $120s into the $160s.
The flip side is just as important. Guardant Health is still losing money, burning roughly $70M in free cash flow last quarter, and posting steep negative margins. Insider selling in June 2026 — including about $12.6M sold by Co‑CEO Helmy Eltoukhy and smaller sales from director Musa Tariq — reminds traders that management is also locking in some gains even while keeping substantial stakes.
This is where trading discipline matters. GH has a bullish backdrop, but it remains a volatile, high‑beta diagnostics name. As Tim Sykes likes to say, “The market doesn’t care about your opinion, it cares about price action — react to what’s actually happening and always, always cut losses quickly.” In the same spirit of focusing on disciplined trading rather than emotions or fear of missing out, As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.”. For Guardant Health, that means respecting the trend, watching how GH behaves around key levels and news catalysts, and treating every trade as a research lesson, not a prediction. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.